TCR2 Therapeutics (TCRR) announced positive results of a Phase 1 trial on Monday, and the stock price is up over 50% in pre-market trading:
Source: Google Finance
TCR2's results may be promising indeed, but for the reasons stated below, traders and shareholders should be concerned about dilution and additional sales described in earlier securities filings.
1. Background and Phase 1 Results
As described in the company's Amended Form S-1, TCR2 is developing T-cell therapies for cancer patients. (I am in no way qualified or experienced with any of the relevant medical